Table 3.
Up-regulated pathways in rat zG.
| significant pathways | p-value | number of genes in pathways |
up-regulated genes | ||||
|---|---|---|---|---|---|---|---|
| ECM | FGFR1c and Klotho ligand binding and activation | 0.010 | 2 | Sdc2 | |||
| Klotho-mediated ligand binding | 0.010 | 2 | Sdc2 | ||||
| FGFR1 ligand binding and activation | 0.021 | 3 | Sdc2 | ||||
| FGFR1c ligand binding and activation | 0.021 | 3 | Sdc2 | ||||
| Integrin cell surface interactions | 0.026 | 24 | Fn1 | Vtn | |||
| Signal Transduction | 0.030 | 68 | Sdc2 | Fn1 | Vtn | ||
| FGFR2 ligand binding and activation | 0.031 | 3 | Sdc2 | ||||
| FGFR2b ligand binding and activation | 0.031 | 3 | Sdc2 | ||||
| FGFR2c ligand binding and activation | 0.031 | 3 | Sdc2 | ||||
| FGFR3b ligand binding and activation | 0.031 | 3 | Sdc2 | ||||
| FGFR3c ligand binding and activation | 0.031 | 3 | Sdc2 | ||||
| FGFR4 ligand binding and activation | 0.031 | 3 | Sdc2 | ||||
| FGFR ligand binding and activation | 0.041 | 5 | Sdc2 | ||||
| FGFR3 ligand binding and activation | 0.041 | 4 | Sdc2 | ||||
| Signaling by FGFR | 0.041 | 5 | Sdc2 | ||||
| cell cycle | S Phase | 0.004 | 10 | Wee1 | Ccnd1 | ||
| Mitotic G1-G1/S phases | 0.005 | 11 | Wee1 | Ccnd1 | |||
| G2/M DNA replication checkpoint | 0.010 | 1 | Wee1 | ||||
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex |
0.021 | 2 | Wee1 | ||||
| Polo-like kinase mediated events | 0.021 | 2 | Wee1 | ||||
| Ubiquitin-dependent degradation of Cyclin D | 0.021 | 2 | Ccnd1 | ||||
| Ubiquitin-dependent degradation of Cyclin D1 | 0.021 | 2 | Ccnd1 | ||||
| G2/M DNA damage checkpoint | 0.031 | 3 | Wee1 | ||||
| Cell Cycle, Mitotic | 0.032 | 31 | Wee1 | Ccnd1 | |||
| G2/M Checkpoints | 0.041 | 4 | Wee1 | ||||
| others | Chemokine receptors bind chemokines | 0.013 | 17 | Cxcl12 | Cxcl16 | ||
| Class A/1 (Rhodopsin-like receptors) | 0.024 | 109 | Cxcl12 | Cxcl16 | Agtr1a | Ptafr | |
| Peptide ligand-binding receptors | 0.027 | 64 | Cxcl12 | Cxcl16 | Agtr1a | ||
| GPCR ligand binding | 0.043 | 131 | Cxcl12 | Cxcl16 | Agtr1a | Ptafr | |
| Ion channel transport | 0.021 | 2 | Atp2a2 | ||||
| Ion transport by P-type ATPases | 0.021 | 2 | Atp2a2 | ||||
| Platelet calcium homeostasis | 0.031 | 3 | Atp2a2 | ||||
| Reduction of cytosolic Ca++ levels | 0.031 | 3 | Atp2a2 | ||||
| Eicosanoids | 0.031 | 3 | Ptgis | ||||
| Prostanoid metabolism | 0.031 | 3 | Ptgis | ||||
| Association of TriC/CCT with target proteins during biosynthesis |
0.010 | 1 | Sphk1 | ||||
| Chaperonin-mediated protein folding | 0.031 | 3 | Sphk1 | ||||
| Notch receptor binds with a ligand | 0.010 | 1 | Jag1 | ||||
FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; GPCR, G protein coupled receptor; Sdc2, syndecan 2 (gene #31) ; Fn1, fibronectin 1 (#110); Vtn, vitronectin (#186); Wee1, WEE1 homolog (#106); Ccnd1, cyclin D1 (#36); Cxcl12, chemokine (C-X-C motif) ligand 12 (#54); Cxcl16, chemokine (C-X-C motif) ligand 16 (#222); Agtr1a, angiotensin II receptor, type 1a (#37); Ptafr, platelet-activating factor receptor (#102); Atp2a2, ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2 (#175); Ptgis, prostaglandin I2 (prostacyclin) synthase (#24); Sphk1, sphingosine kinase 1 (#124); Jag1, jagged 1 (#91). The detail of genes are shown in Supplemental Table 1.